Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin

Canan Schumann, Stephanie Chan, Jess A. Millar, Yuliya Bortnyak, Katherine Carey, Alex Fedchyk, Leon Wong, Tetiana Korzun, Abraham S. Moses, Anna Lorenz, Delany Shea, Olena Taratula, Oleh Khalimonchuk, Oleh Taratula

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1 siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates the DJ-1 protein in metastatic ovarian cancer tumors and ascites. In vivo experiments revealed that DJ-1 siRNA monotherapy outperformed cisplatin alone by inhibiting tumor growth and increasing survival of mice with metastatic ovarian cancer. Finally, three cycles of siRNA-mediated DJ-1 therapy in combination with a low dose of cisplatin completely eradicated ovarian cancer tumors from the mice, and there was no cancer recurrence detected for the duration of the study, which lasted 35 weeks.

Original languageEnglish (US)
Pages (from-to)1395-1405
Number of pages11
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number4
DOIs
StatePublished - Jun 1 2018

Fingerprint

Ovarian Neoplasms
Small Interfering RNA
Cisplatin
Tumors
Proteins
Neoplasms
Cells
Growth
Intraperitoneal Injections
Ascites
Therapeutics
Down-Regulation
Protein Deglycase DJ-1
Recurrence
Experiments

Keywords

  • DJ-1
  • cisplatin
  • combinatorial therapy
  • ovarian cancer
  • siRNA

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. / Schumann, Canan; Chan, Stephanie; Millar, Jess A.; Bortnyak, Yuliya; Carey, Katherine; Fedchyk, Alex; Wong, Leon; Korzun, Tetiana; Moses, Abraham S.; Lorenz, Anna; Shea, Delany; Taratula, Olena; Khalimonchuk, Oleh; Taratula, Oleh.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 4, 01.06.2018, p. 1395-1405.

Research output: Contribution to journalArticle

Schumann, C, Chan, S, Millar, JA, Bortnyak, Y, Carey, K, Fedchyk, A, Wong, L, Korzun, T, Moses, AS, Lorenz, A, Shea, D, Taratula, O, Khalimonchuk, O & Taratula, O 2018, 'Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 14, no. 4, pp. 1395-1405. https://doi.org/10.1016/j.nano.2018.03.005
Schumann, Canan ; Chan, Stephanie ; Millar, Jess A. ; Bortnyak, Yuliya ; Carey, Katherine ; Fedchyk, Alex ; Wong, Leon ; Korzun, Tetiana ; Moses, Abraham S. ; Lorenz, Anna ; Shea, Delany ; Taratula, Olena ; Khalimonchuk, Oleh ; Taratula, Oleh. / Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 4. pp. 1395-1405.
@article{f1b56e457d52475a8928fbac54fdf2a7,
title = "Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin",
abstract = "Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1 siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates the DJ-1 protein in metastatic ovarian cancer tumors and ascites. In vivo experiments revealed that DJ-1 siRNA monotherapy outperformed cisplatin alone by inhibiting tumor growth and increasing survival of mice with metastatic ovarian cancer. Finally, three cycles of siRNA-mediated DJ-1 therapy in combination with a low dose of cisplatin completely eradicated ovarian cancer tumors from the mice, and there was no cancer recurrence detected for the duration of the study, which lasted 35 weeks.",
keywords = "DJ-1, cisplatin, combinatorial therapy, ovarian cancer, siRNA",
author = "Canan Schumann and Stephanie Chan and Millar, {Jess A.} and Yuliya Bortnyak and Katherine Carey and Alex Fedchyk and Leon Wong and Tetiana Korzun and Moses, {Abraham S.} and Anna Lorenz and Delany Shea and Olena Taratula and Oleh Khalimonchuk and Oleh Taratula",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.nano.2018.03.005",
language = "English (US)",
volume = "14",
pages = "1395--1405",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin

AU - Schumann, Canan

AU - Chan, Stephanie

AU - Millar, Jess A.

AU - Bortnyak, Yuliya

AU - Carey, Katherine

AU - Fedchyk, Alex

AU - Wong, Leon

AU - Korzun, Tetiana

AU - Moses, Abraham S.

AU - Lorenz, Anna

AU - Shea, Delany

AU - Taratula, Olena

AU - Khalimonchuk, Oleh

AU - Taratula, Oleh

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1 siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates the DJ-1 protein in metastatic ovarian cancer tumors and ascites. In vivo experiments revealed that DJ-1 siRNA monotherapy outperformed cisplatin alone by inhibiting tumor growth and increasing survival of mice with metastatic ovarian cancer. Finally, three cycles of siRNA-mediated DJ-1 therapy in combination with a low dose of cisplatin completely eradicated ovarian cancer tumors from the mice, and there was no cancer recurrence detected for the duration of the study, which lasted 35 weeks.

AB - Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1 siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates the DJ-1 protein in metastatic ovarian cancer tumors and ascites. In vivo experiments revealed that DJ-1 siRNA monotherapy outperformed cisplatin alone by inhibiting tumor growth and increasing survival of mice with metastatic ovarian cancer. Finally, three cycles of siRNA-mediated DJ-1 therapy in combination with a low dose of cisplatin completely eradicated ovarian cancer tumors from the mice, and there was no cancer recurrence detected for the duration of the study, which lasted 35 weeks.

KW - DJ-1

KW - cisplatin

KW - combinatorial therapy

KW - ovarian cancer

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85047151315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047151315&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.03.005

DO - 10.1016/j.nano.2018.03.005

M3 - Article

VL - 14

SP - 1395

EP - 1405

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 4

ER -